Novartis’ Asciminib (ABL001) Demonstrate Superiority Over Pfizer’s Bosulif in Chronic Myeloid Leukemia Trial

Shots:

  • The P-lll ASCEMBL study involves assessing Asciminib (40mg, bid) vs Bosulif (bosutinib, 500mg, qd) in 223 patients with Ph+ CML-CP prior treated with two or more TKIs and the data were presented at 62nd (ASH) Annual Meeting & Exposition
  • Results: @ 24 wks. MMR rate (25.5% vs 13.2%) tCCyR rate (40.8% vs 24.2%); DMR rate were higher with patients achieving MR4 and MR5(10.8% and 8.9% vs 5.3% and 1.3%); Grade ≥3 AEs (50.6% and 60.5%) respectively, presented at ASH
  • The US FDA has granted FT designation for Asciminib while the regulatory submission to the US and EU health authorities is planned for H1’21

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: PMLiVE

The post Novartis’ Asciminib (ABL001) Demonstrate Superiority Over Pfizer’s Bosulif in Chronic Myeloid Leukemia Trial first appeared on PharmaShots.

Novartis Reports Results of Asciminib (ABL001) in P-III ASCEMBL Study for Chronic Myeloid Leukemia

Shots:

  • The P-III ASCEMBL study involves assessing of Asciminib (ABL001) vs bosutinib in patients with Ph+ CML-CP, prior treated with two or more TKIs
  • The study met its 1EPs of superiority in major molecular response (MMR) rate @24wks.
  • Asciminib (ABL001) is an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP), being evaluated in multiple clinical studies addressing the needs of CML patients. The US FDA has granted FT designation for the therapy

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Fortune